Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Marianne Sadar

British Columbia Cancer Agency, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Essa Pharma Inc.

Disclosed Value
Listed Reason
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)

There is a perceived financial conflict of interest (FCOI) between Dr. Marianne Sadar’s NIH funded research and her interest in the private company ESSA Pharmaceuticals Inc., which Marianne co-founded. It could be perceived that her NIH project research outcomes that are not favorable to ESSA's financial outlook may not be presented. However, this is mitigated by the management plan. Change in financial value happened in 2015 due to the fact that ESSA became a publicly traded company in January 2015. Estimated value of equity will fluctuate and reflects that of the time of disclosure by inventor. As a result of the liquidity event triggered by ESSA stock trading on the TSX‐V exchange, the founders shares acquired real value, even though their stock is still locked up and untradeable.

Listed Research Project
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics

Once prostate cancer becomes castration-resistant there are no long-term or curative therapies that can be offered and the patient will succumb to his disease in a few years. There is mounting evidence supporting the concept that development of castration-resistant disease is causally related to molecular changes affecting the androgen receptor that include expression of constitutively active truncated splice variants that lack a C-terminus ligand-binding domain. Here we propose studies to reveal the mechanisms of antagonists of androgen receptor activation function-1 for further development of novel therapeutics that will delay or prevent hormonal progression to the terminal stage of prostate cancer.

Filed on March 16, 2017.

Tell us what you know about Marianne Sadar's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Marianne Sadar Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $500,000 - $549,999
Marianne Sadar Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $500,000 - $549,999
Marianne Sadar Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $150,000 - $199,999
Marianne Sadar Provincial Health Services Authority Conflict of Interest Essa Pharma Inc. $150,000 - $199,999
Marianne Sadar British Columbia Cancer Agency Conflict of Interest Essa Pharma Inc. $150,000 - $199,999
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page